A MedCity News report indicates Nabriva Therapeutics has raised more than $100 million for drugs that treat highly resistant bacterial infections.
The first $50 million will go toward bringing its lead antibiotic, lefamulin, into phase 3 trials to treat community-acquired bacterial pneumonia.
The biotech, which is based both in Austria and Philadelphia, received the financing from new investors Vivo Capital and Orbimed Investors, who led the round. EcoR1, Boxer Capital of Tavistock Life Sciences, HB, Phase 4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund. Vivo Capital and OrbiMed reps will join the startup’s supervisory board.
“We believe Nabriva is one of a few development stage companies with a truly novel antibiotic product ready for phase 3 studies and with a clear path to commercialization,” Dr. Chen Yu, a managing partner at Vivo Capital, said in a statement.